公开(公告)号：AU2011376953B2

公开(公告)日：2017-08-24

申请号：AU2011376953

申请日：2011-09-13

Applicant: LES LABORATOIRES SERVIER SAS ,  PHARMACYCLICS INC

Inventor： LOURY DAVID J ,  BUGGY JOSEPH J ,  MODY TARAK D ,  VERNER ERIK J ,  PURRO NORBERT ,  BALASUBRAMANIAN SRIRAM ,  KLOOS IOANA ,  DEPIL STEPHANE

IPC: A61K31/343 ,  A61K31/16 ,  A61K31/166 ,  A61P35/00

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

公开(公告)号：CA2847011A1

公开(公告)日：2013-03-14

申请号：CA2847011

申请日：2012-09-07

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STEPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K31/138 ,  A61K31/343 ,  A61K31/704 ,  A61K33/24 ,  A61P35/00

Abstract: NOUVEAU SCHEMA D'ADMINISTRATION DU W-HYDROXY-4-{2-[3-(W,W-DIMETHYLAMINOMETHYL)BENZOFU- RAN-2-YLCARBONYLAMINO]ETHOXY} BENZAMIDE /V-hydroxy-4-{2-[3-{/V,/V-diméthylaminométhyl)benzofu- ran-2-ylcarbonylamino]éthoxy} benzamide de formule (I) : ou un de ses sels d'addition à un acide ou à une base pharmaceutiquement acceptable, seul ou en association avec un traitement de chirurgie, de chimiothérapie, d'hormonothérapie ou avec la radiothérapie, pour le traitement du cancer, caractérisé en ce qu'il est administré pendant 4 jours consécutifs, cette période étant suivie de 3 jours consécutifs sans aucune administration du composé de formule (I), étant entendu que le traitement de chimiothérapie n'est pas le FOLFOX.

公开(公告)号：FR2977492B1

公开(公告)日：2013-07-05

申请号：FR1102087

申请日：2011-07-04

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： DEPIL STEPHANE ,  JACQUET BESCOND ANNE ,  KLOOS IOANA ,  SARRY ANNE LAURE ,  BALASUBRAMANIAN SRIRAM ,  BUGGY JOSEPH

IPC: A61K31/343 ,  A61K31/282 ,  A61K31/513 ,  A61K31/519 ,  A61P35/00

公开(公告)号：CA2845806C

公开(公告)日：2019-06-11

申请号：CA2845806

申请日：2011-09-13

Applicant: PHARMACYCLICS INC ,  LES LABORATOIRES SERVIER SAS

Inventor： LOURY DAVID J ,  BUGGY JOSEPH J ,  MODY TARAK D ,  VERNER ERIK J ,  PURRO NORBERT ,  BALASUBRAMANIAN SRIRAM ,  KLOOS IOANA ,  DEPIL STEPHANE

IPC: A61K31/4184 ,  A61K31/16 ,  A61K31/343 ,  A61K31/47 ,  A61P35/00

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

公开(公告)号：AU2016202594A1

公开(公告)日：2016-05-19

申请号：AU2016202594

申请日：2016-04-22

Applicant: PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STEPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K31/138 ,  A61K31/343 ,  A61K31/704 ,  A61K33/24 ,  A61P35/00

Abstract: NEW ADMINISTRATION REGIME FOR N-HYDROXY-4-{2-[3-(N,N-DIMETHYLAMINOMETHYL)BENZOFURAN-2 YLCARBONYLAMINO]ETHOXY}BENZAMIDE N-hydroxy-4-12-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy} benzamide of formula (I): H(J _0 =0 or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with a surgery, chemotherapy, hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that chemotherapy is not FOLFOX. Medicaments are also disclosed.

公开(公告)号：UY34295A

公开(公告)日：2013-04-30

申请号：UY34295

申请日：2012-08-28

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： JACQUET-BESCOND ANNE ,  IOANA KLOOS ,  MARYLORE CHENEL ,  RENATA ROBERT ,  SRIRAM BALASUBRAMANIAN ,  DEPIL STEPHANE ,  FOULIARD SYLVAIN

IPC: A61K31/34 ,  A61K31/343 ,  A61P31/00 ,  A61P35/00 ,  C07D307/77 ,  C07D307/78

Abstract: N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida de fórmula I,o de una de sus sales de adición a un ácido o a una base farmacéuticamente aceptable, solo o en asociación con un tratamiento de cirugía, de quimioterapia, de hormonoterapia o con radioterapia para su utilización en el tratamiento del cáncer, caracterizada porque se administra durante 4 días consecutivos, estando seguido este periodo de 3 díasconsecutivos sin ninguna administración del compuesto de fórmula (I), con la salvedad de que el tratamiento de quimioterapia no es el FOLFOX. Medicamentos.

公开(公告)号：FR2977492A1

公开(公告)日：2013-01-11

申请号：FR1102087

申请日：2011-07-04

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： DEPIL STEPHANE ,  JACQUET BESCOND ANNE ,  KLOOS IOANA ,  SARRY ANNE LAURE ,  BALASUBRAMANIAN SRIRAM ,  BUGGY JOSEPH

IPC: A61K31/343 ,  A61K31/282 ,  A61K31/513 ,  A61K31/519 ,  A61P35/00

Abstract: Association entre le N-hydroxy-4-{2-[3-(N,N-diméthylaminométhyl)benzofuran-2-ylcarbonylamino]éthoxy}benzamide de formule (I) : ou un de ses sels d'addition à un acide ou à une base pharmaceutiquement acceptable et le FOLFOX. Médicaments.

公开(公告)号：AU2012306122A1

公开(公告)日：2014-03-13

申请号：AU2012306122

申请日：2012-09-07

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STEPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K31/138 ,  A61K31/343 ,  A61K31/704 ,  A61K33/24 ,  A61P35/00

Abstract: A novel scheme for administering N-hydroxy-4-{2-[3-{N,N-dimethylaminomethyl)benzofuran-2-ylcarbonyl­amino]ethoxy}benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in combination with a surgical, chemotherapy or hormone therapy treatment or with radiotherapy, for the treatment of cancer, characterized in that it is administered for 4 consecutive days, this period being followed by 3 consecutive days without any administration of the compound of formula (I), wherein it is understood that the chemotherapy treatment is not FOLFOX.

公开(公告)号：CA2845806A1

公开(公告)日：2013-03-21

申请号：CA2845806

申请日：2011-09-13

Applicant: PHARMACYCLICS INC ,  SERVIER SAS LAB

Inventor： LOURY DAVID J ,  BUGGY JOSEPH J ,  MODY TARAK D ,  VERNER ERIK J ,  PURRO NORBERT ,  BALASUBRAMANIAN SRIRAM ,  KLOOS IOANA ,  DEPIL STEPHANE

IPC: A61K31/4184 ,  A61K31/16 ,  A61K31/343 ,  A61K31/47 ,  A61P35/00

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

公开(公告)号：UA110853C2

公开(公告)日：2016-02-25

申请号：UAA201402905

申请日：2011-09-13

Applicant: PHARMACYCLICS INC

Inventor： LOURY DAVID J ,  BUGGY JOSEPH J ,  MODY TARAK D ,  VERNER ERIK J ,  PURRO NORBERT ,  BALASUBRAMANIAN SRIRAM ,  KLOOS IOANA ,  DEPIL STEPHANE

IPC: A61K31/343 ,  A61K31/16 ,  A61K31/166 ,  A61P35/00 ,  C07D213/68 ,  C07D307/78 ,  C07D491/10

Abstract: Винахідстосуєтьсяфармацевтичноїкомпозиції, міститьінгібіторгістодеацетилази (HDAC), бендамустині фармацевтичноприйнятнудопоміжнуречовину, комбінаціїбендамустинуабойогофармацевтичноприйнятногоскладногоефіру, соліабосольватутаінгібітора HDAC ізастосуваннятакоїкомбінаціїдлялікуванняракуу пацієнта, якийцьогопотребує.